CVS Health Corporation $CVS Shares Sold by Bleakley Financial Group LLC

Key Points

• Bleakley Financial Group cut its CVS Health stake by 39.2% in the fourth quarter, selling 25,268 shares and ending with 39,218 shares worth about $3.1 million.
• Wall Street remains constructive on CVS: several analysts raised price targets, and the stock carries a consensus “Moderate Buy” rating with an average target price of $98.88.
• CVS reported strong quarterly results, beating earnings and revenue estimates, while also paying a quarterly dividend of $0.665 per share for a 2.9% yield.

Bleakley Financial Group LLC lessened its holdings in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 39.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 39,218 shares of the pharmacy operator's stock after selling 25,268 shares during the quarter. Bleakley Financial Group LLC's holdings in CVS Health were worth $3,112,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in CVS Health by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator's stock valued at $9,579,508,000 after purchasing an additional 1,824,424 shares in the last quarter. Capital World Investors lifted its holdings in CVS Health by 2.1% during the 3rd quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator's stock worth $5,155,380,000 after buying an additional 1,419,575 shares during the last quarter. State Street Corp lifted its holdings in CVS Health by 0.3% during the 3rd quarter. State Street Corp now owns 58,938,286 shares of the pharmacy operator's stock worth $4,443,357,000 after buying an additional 149,701 shares during the last quarter. Capital International Investors lifted its holdings in CVS Health by 1.1% during the 3rd quarter. Capital International Investors now owns 26,692,203 shares of the pharmacy operator's stock worth $2,012,347,000 after buying an additional 302,499 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in CVS Health by 3.2% during the 3rd quarter. Invesco Ltd. now owns 24,293,058 shares of the pharmacy operator's stock worth $1,831,454,000 after buying an additional 760,579 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company's stock.

Analyst Ratings Changes

CVS has been the topic of a number of research analyst reports. UBS Group increased their target price on CVS Health from $97.00 to $100.00 and gave the stock a "buy" rating in a report on Thursday, May 7th. The Goldman Sachs Group increased their target price on CVS Health from $95.00 to $97.00 and gave the stock a "buy" rating in a report on Thursday, February 12th. HSBC increased their target price on CVS Health from $83.00 to $85.00 and gave the stock a "hold" rating in a report on Tuesday, May 5th. Leerink Partners reaffirmed an "outperform" rating and set a $98.00 target price on shares of CVS Health in a report on Thursday, March 5th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on CVS Health from $88.00 to $92.00 and gave the stock a "buy" rating in a report on Thursday, May 7th. Twenty-two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, CVS Health has an average rating of "Moderate Buy" and a consensus target price of $98.88.

Insider Buying and Selling at CVS Health

In related news, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the transaction, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. The trade was a 87.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Larry Robbins sold 1,983,538 shares of CVS Health stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the transaction, the director owned 6,213,261 shares in the company, valued at $586,842,501.45. The trade was a 24.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is owned by insiders.

CVS Health Stock Up 1.4%

CVS opened at $92.02 on Thursday. CVS Health Corporation has a 12 month low of $58.50 and a 12 month high of $98.43. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The stock has a market cap of $117.41 billion, a P/E ratio of 40.54, a P/E/G ratio of 0.89 and a beta of 0.60. The stock's 50 day moving average price is $81.35 and its 200 day moving average price is $79.37.

CVS Health (NYSE:CVS - Get Free Report) last posted its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm had revenue of $100.43 billion for the quarter, compared to analysts' expectations of $94.99 billion. During the same period last year, the firm earned $2.25 EPS. The firm's revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, research analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd were given a dividend of $0.665 per share. The ex-dividend date was Thursday, April 23rd. This represents a $2.66 annualized dividend and a dividend yield of 2.9%. CVS Health's dividend payout ratio (DPR) is 117.18%.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Barclays raised its price target on CVS Health to $106 from $101 and maintained an overweight rating, signaling improved Wall Street confidence in the stock’s upside. Barclays price target raise
• Positive Sentiment: Aetna said its second-generation Claims Assist Manager, an AI-powered claims platform, has cut claims processing time by more than 20% while improving payment accuracy, a potential margin and efficiency tailwind for CVS Health. Aetna AI claims update
• Positive Sentiment: MinuteClinic and Hartford HealthCare expanded primary care access across Connecticut, adding another growth-oriented partnership that could help CVS broaden patient access and utilization. MinuteClinic Hartford HealthCare expansion
• Positive Sentiment: Aetna Better Health of Missouri announced a $175,000 community investment to address food insecurity and safety/wellness supports, reinforcing CVS Health’s Medicaid/community-health positioning. Aetna Missouri community investment
• Neutral Sentiment: CVS Health is also drawing attention for broader analyst commentary, but the article provided did not include a clear new catalyst beyond market discussion. Analyst commentary on CVS Health
• Negative Sentiment: CVS sued Tennessee over a new PBM-pharmacy ownership law, arguing it unlawfully targets out-of-state companies and could force the company to shut pharmacies in the state, creating regulatory and earnings risk. CVS Tennessee lawsuit

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.